2023 Nov 1 -15
SITC 2023 (poster 381)
SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function
- Phase 1 clinical outcomes indicate; 1) pristine safety in all 28 end-stage cancer patients treated with SUPLEXA cells, 2) Complete or partial responses in MSI-Hcolorectal cancer patients and stable disease in renal cell carcinoma and melanoma patients.
- Immunomodulation of blood activated classical monocytes and PMN-MDSCs in CRC patients showing beneficial clinical responses to SUPLEXA therapeutic cells.
- Circulating cytokines and biomarkers are significantly modulated by SUPLEXA cell treatments.